Header

Header

Header

Antibody–Drug Bioconjugation Services

Custom antibody–drug bioconjugation services for ADC development using whole antibodies, IgG, IgM, and antibody fragments with cytotoxic drugs, antibiotics, vitamins, biotin, and other small-molecule payloads.

Whole antibodies • IgG • IgM • fragments Cancer drugs • antibiotics • vitamins/biotin Site-aware conjugation planning Discovery to preclinical support

Overview

Antibody–drug conjugation (ADC) enables precise delivery of therapeutic and functional payloads by leveraging the specificity of antibodies. By combining targeted binding with potent small-molecule compounds, ADCs are widely used in oncology research, targeted delivery systems, and advanced diagnostic applications.

We provide customized ADC conjugation services across multiple antibody formats and payload classes, with optimized chemistries designed to preserve antibody activity and ensure controlled payload attachment.

From feasibility studies to preclinical development, our capabilities include conjugation strategy design, linker selection, purification, and analytical characterization to deliver consistent, high-quality conjugates.

Antibody drug bioconjugation diagram showing antibody, linker, and drug payload
Carrier Selection

Antibody-first planning

Carrier selection affects DAR control, steric accessibility, purification behavior, and assay compatibility.

Payload Function

Payload-class grouping

Grouping by payload type helps users identify whether they need cytotoxic, antimicrobial, affinity, or other small-molecule functions.

UX Content

Application-focused design

Conjugation strategies are selected to align antibody format, payload properties, linker design, and downstream application requirements.

Antibody formats we can use for conjugation

We support conjugation across multiple antibody formats, each offering distinct advantages depending on the application, targeting requirements, and desired conjugation strategy.

Antibody Format Examples Typical Applications Conjugation Considerations
Whole Antibodies Full-length monoclonal antibodies Therapeutic targeting, immunoassays, ADC development Supports lysine and cysteine conjugation; Fc region may influence steric accessibility and DAR distribution.
IgG IgG1, IgG2 recombinant antibodies Standard ADC platforms, targeted delivery, assay development Most widely used format; enables controlled conjugation and well-characterized linker strategies.
IgM Pentameric or hexameric IgM High-avidity binding applications, specialized targeting systems Complex structure may impact conjugation uniformity, aggregation, and analytical characterization.
Antibody Fragments Fab, F(ab')₂, scFv Improved tissue penetration, imaging, modular constructs Smaller size improves accessibility; linker design and site selection are critical to maintain binding.

Antibody–Drug Payload Classes

Expand a payload class to view representative examples, payload type, typical function, and conjugation notes.

Cancer drug payloads anthracyclines • taxanes • vinca alkaloids • topo agents
Cytotoxic payloads Targeted delivery Release-model sensitive
Payload class Representative payloads Drug type Typical function Conjugation notes
Anthracyclines Doxorubicin, Epirubicin, Daunorubicin, Idarubicin DNA-intercalating cytotoxics Targeted cancer payload delivery Linker choice is often driven by release vs stability; evaluate redox and pH sensitivity.
Taxanes Paclitaxel, Docetaxel, Tesetaxel Microtubule agents Cytotoxic payload exploration Hydrophobicity can affect purification and handling; spacers such as PEG may improve solubility.
Vinca alkaloids Vincristine, Vinblastine, Vinorelbine Microtubule agents ADC-style cytotoxic delivery Site-defined attachment helps manage stoichiometry and reduce heterogeneity.
Topoisomerase agents Etoposide, Irinotecan, Topotecan Topo inhibitors DNA/topo-directed payload class Assess reactive handles and stability early; define loading and purity criteria up front.
Antibiotic payloads antimicrobial classes • delivery-focused constructs • project-dependent feasibility
Antimicrobial Handle planning Stability-sensitive
Payload class Representative payloads Drug type Typical function Conjugation notes
Rifamycins Rifampicin derivatives Antibiotic Antimicrobial payload exploration Plan chemistry to preserve sensitive motifs and clarify whether payload release is required.
Fluoroquinolones Ciprofloxacin, Levofloxacin Antibiotic DNA gyrase/topo antimicrobial activity Handle placement should avoid disrupting key pharmacophores; spacer length may reduce steric masking.
Aminoglycosides Gentamicin, Neomycin, Tobramycin Antibiotic Antimicrobial payload class Highly polar or cationic character can influence purification and loading analysis.
Vitamins & biotin affinity tags • targeting ligands • assay and delivery support
Biotin systems Affinity support Targeting ligands
Payload class Representative payloads Drug type Typical function Conjugation notes
Biotin Biotin and biotin derivatives Affinity label Streptavidin/avidin capture and detection Excellent for assay workflows; linker length can reduce steric interference in binding systems.
Folate / vitamin ligands Folic acid, vitamin B12 derivatives Targeting or functional ligand Receptor interaction or functional tagging Useful when a vitamin-derived motif is part of the targeting or assay concept; chemistry depends on available handles.
Other drug-like small molecules kinase inhibitors • immune modulators • fluorescent or custom compounds
Custom small molecules Research use Feasibility-driven
Payload class Representative payloads Drug type Typical function Conjugation notes
Kinase inhibitors Custom kinase inhibitor derivatives Targeted small molecule Mechanistic or functional modulation Attachment must preserve the active pharmacophore and should be planned around a unique handle.
Immune modulators Custom immunomodulatory small molecules Functional small molecule Immune signaling or modulation studies Payload stability, polarity, and release model should be defined before route selection.
Fluorescent / reporter small molecules Reporter dyes, imaging-active small molecules Label / probe Tracking, imaging, assay development Often benefit from spacer design to reduce quenching or steric interference.
Other custom compounds Project-specific synthetic small molecules Drug-like research payload Custom therapeutic or assay function Feasibility depends on functional groups, stability, solubility, and the desired linker model.

ADC Development Workflow

Our ADC development workflow is designed to support projects from early feasibility through purification, characterization, and scale-up planning.

ADC development workflow showing conjugation strategy design, conjugation process, purification, characterization, and scalable manufacturing

From discovery to preclinical supply, we deliver high-quality ADCs tailored to your research and development needs.

FAQ

How much antibody is required for antibody–drug conjugation?

Most projects require approximately 2–5 mg of antibody to generate ~1 mg of purified conjugate. Actual yield depends on antibody format, conjugation chemistry, purification efficiency, and target drug-to-antibody ratio (DAR).

What types of antibodies can be used for conjugation?

We support conjugation of whole antibodies, IgG, IgM, and antibody fragments (Fab, F(ab')₂, scFv). The optimal format depends on your application, targeting requirements, and desired conjugation strategy.

What types of payloads can be conjugated to antibodies?

We work with a wide range of payloads including cytotoxic cancer drugs, antibiotics, biotin and vitamins, and other small molecules. Feasibility depends on functional groups, stability, and compatibility with conjugation chemistry.

How do you control the drug-to-antibody ratio (DAR)?

DAR is controlled through the selection of conjugation chemistry (e.g., lysine, cysteine, or site-specific methods) and reaction conditions. We optimize parameters to achieve consistent and application-appropriate loading levels.

Will antibody binding activity be affected after conjugation?

Conjugation strategies are designed to minimize impact on antigen-binding activity. Site selection, linker design, and reaction conditions are optimized to preserve antibody functionality.

What information do I need to provide to start a project?

Please provide the antibody format, payload or payload class, desired conjugation strategy (if known), quantity, and intended application. Including datasheets or structural details will help streamline feasibility evaluation.

Contact & Quote Request

For the fastest review, please share your antibody format, payload or payload class, preferred conjugation strategy if known, target quantity, and intended application. This helps us recommend a practical conjugation approach, suitable linker options, and the most appropriate purification and analytical workflow for your project.

Best results start with the right project details: whether your goal is targeted therapeutic development, assay design, proof-of-concept evaluation, or custom bioconjugate preparation, we can help define a workflow aligned to your molecule and application.

Helpful Details to Include

  • Antibody format: whole antibody, IgG, IgM, Fab, F(ab')₂, scFv, or other fragment
  • Payload or payload class: cancer drug, antibiotic, biotin/vitamin, or other small molecule
  • Preferred conjugation chemistry or linker type, if known
  • Target application: therapeutic research, assay development, imaging, or custom bioconjugation
  • Quantity required and any purity or characterization expectations
  • Special handling, buffer, or formulation requirements if applicable

Fastest Path

Send your project details directly and our team can review feasibility, conjugation options, and next steps.

After review, we can recommend an antibody format, payload attachment strategy, and supporting workflow based on your project goals.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.